# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 15 | 10.0 | 150.1 | (83.9-247.5) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 11.0 | 45.3 | (14.6-105.6) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.3 | 93.5 | (30.1-218.1) |  | Male | 26 | 38.3 | 68.0 | (44.4-99.6) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 36 | 32.6 | 110.4 | (77.3-152.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

163

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 42.9 | 58.3 | (37.7-86.0) |  | Male | 26 | 26.1 | 99.7 | (65.1-146.1) |
| Female | 6 | 15.8 | 38.1 | (13.9-82.9) |  | Female | 25 | 20.1 | 124.7 | (80.7-184.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 7.4 | 81.5 | (29.8-177.3) |  | Male | 13 | 8.4 | 154.8 | (82.3-264.7) |
| Female | 5 | 6.3 | 80.0 | (25.8-186.6) |  | Female | 6 | 7.0 | 85.9 | (31.4-187.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 21 | 23.4 | 89.8 | (55.5-137.2) |
| Female | 164 | 162.3 | 101.0 | (86.2-117.7) |  | Female | 24 | 21.2 | 113.2 | (72.5-168.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 18.2 | 82.3 | (46.0-135.8) |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 8 | 8.9 | 90.2 | (38.8-177.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 44.7 | 78.2 | (54.5-108.8) |  |  |  |  |  |  |
| Female | 31 | 47.3 | 65.5 | (44.5-93.0) |  | Female | 20 | 14.5 | 138.0 | (84.3-213.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 10.9 | nc | (nc-nc) |  | Male | 12 | 14.8 | 81.2 | (41.9-141.9) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 18 | 15.9 | 113.5 | (67.2-179.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  | Male | 140 | 134.3 | 104.3 | (87.7-123.0) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 21.7 | 96.8 | (59.9-148.0) |  | Male | 3 | 9.8 | nc | (nc-nc) |
| Female | 8 | 13.1 | 61.2 | (26.4-120.6) |  | Female | 8 | 6.1 | 131.0 | (56.4-258.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 16.4 | 115.5 | (69.5-180.4) |  | Male | 10 | 9.0 | 110.6 | (52.9-203.4) |
| Female | 12 | 12.2 | 98.6 | (50.9-172.3) |  | Female | 36 | 26.1 | 137.8 | (96.5-190.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 13.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 30 | 36.9 | 81.4 | (54.9-116.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 74.9 | 46.7 | (32.6-65.0) |  | Male | 428 | 533.9 | 80.2 | (72.7-88.1) |
| Female | 48 | 81.3 | 59.1 | (43.5-78.3) |  | Female | 503 | 558.0 | 90.1 | (82.4-98.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

164

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 3.7 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 11 | 12.4 | 88.7 | (44.2-158.7) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 5 | 11.7 | 42.9 | (13.8-100.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

165

# Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 8.9 | 56.4 | (18.2-131.7) |  | Male | 5 | 5.1 | 98.4 | (31.7-229.6) |
| Female | 7 | 2.3 | 305.5 | (122.4-629.4) |  | Female | 7 | 3.3 | 214.3 | (85.9-441.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.6 | 108.6 | (35.0-253.3) |
| Female | 41 | 25.2 | 162.9 | (116.9-221.0) |  | Female | 5 | 3.2 | 154.7 | (49.9-361.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.3 | 153.7 | (49.5-358.7) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 9.0 | 88.9 | (38.3-175.3) |  |  |  |  |  |  |
| Female | 8 | 7.2 | 111.2 | (47.9-219.1) |  | Female | 5 | 2.2 | 222.3 | (71.6-518.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 6 | 2.9 | 204.0 | (74.5-444.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 45 | 22.7 | 198.5 | (144.8-265.7) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.4 | 179.1 | (65.4-389.8) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 7 | 2.0 | 351.8 | (141.0-724.9) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 9 | 5.7 | 158.8 | (72.5-301.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 14.4 | 48.8 | (19.5-100.5) |  | Male | 122 | 101.0 | 120.8 | (100.3-144.3) |
| Female | 8 | 11.6 | 68.7 | (29.6-135.5) |  | Female | 122 | 86.0 | 141.9 | (117.8-169.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

166

# Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 8.8 | 147.7 | (78.6-252.7) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 5.4 | 167.1 | (76.3-317.3) |
| Female | 33 | 42.0 | 78.6 | (54.1-110.4) |  | Female | 6 | 5.3 | 113.9 | (41.6-248.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 10.0 | 60.1 | (21.9-130.8) |  |  |  |  |  |  |
| Female | 9 | 11.6 | 77.3 | (35.3-146.8) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 5 | 3.2 | 156.4 | (50.4-365.0) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 35 | 31.1 | 112.4 | (78.3-156.4) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 8 | 7.5 | 107.3 | (46.2-211.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 11 | 9.4 | 117.5 | (58.6-210.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 16.3 | 128.8 | (79.7-196.9) |  | Male | 124 | 121.6 | 102.0 | (84.8-121.6) |
| Female | 9 | 19.7 | 45.6 | (20.8-86.6) |  | Female | 108 | 141.3 | 76.5 | (62.7-92.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

167

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 22.2 | 53.9 | (27.8-94.2) |  | Male | 20 | 13.2 | 152.0 | (92.8-234.7) |
| Female | 7 | 7.8 | 89.3 | (35.8-183.9) |  | Female | 13 | 9.8 | 132.4 | (70.4-226.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 8 | 11.9 | 67.4 | (29.0-132.8) |
| Female | 78 | 76.4 | 102.1 | (80.7-127.5) |  | Female | 14 | 10.3 | 135.4 | (74.0-227.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 9.0 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 1 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 23.1 | 56.3 | (29.9-96.2) |  |  |  |  |  |  |
| Female | 13 | 24.1 | 54.0 | (28.7-92.3) |  | Female | 6 | 7.0 | 85.7 | (31.3-186.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 3 | 7.6 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 4 | 8.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 66 | 66.5 | 99.3 | (76.8-126.3) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 10.7 | 84.2 | (38.4-159.8) |  | Male | 6 | 5.0 | 119.1 | (43.5-259.3) |
| Female | 4 | 6.2 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 8.3 | 144.6 | (74.6-252.7) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 2 | 6.2 | nc | (nc-nc) |  | Female | 7 | 12.6 | 55.5 | (22.2-114.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 2.3 | 216.8 | (69.9-506.0) |  | Female | 9 | 17.0 | 53.0 | (24.2-100.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 37.9 | 50.1 | (30.2-78.3) |  | Male | 215 | 269.2 | 79.9 | (69.6-91.3) |
| Female | 22 | 38.4 | 57.2 | (35.9-86.7) |  | Female | 225 | 269.6 | 83.4 | (72.9-95.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

168

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 82 | 81.8 | 100.3 | (79.7-124.5) |  | Male | 34 | 57.0 | 59.7 | (41.3-83.4) |
| Female | 46 | 33.0 | 139.5 | (102.1-186.1) |  | Female | 34 | 51.1 | 66.6 | (46.1-93.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 17 | 19.3 | 87.9 | (51.2-140.8) |  | Male | 21 | 17.2 | 122.3 | (75.7-187.0) |
| Female | 16 | 16.3 | 98.3 | (56.2-159.6) |  | Female | 21 | 14.9 | 141.1 | (87.3-215.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 53 | 51.2 | 103.6 | (77.6-135.5) |
| Female | 312 | 373.9 | 83.5 | (74.4-93.2) |  | Female | 32 | 47.2 | 67.7 | (46.3-95.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 52 | 41.9 | 124.1 | (92.7-162.7) |
| Female | 18 | 14.1 | 127.8 | (75.7-202.0) |  | Female | 7 | 19.8 | 35.4 | (14.2-73.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 91 | 92.7 | 98.2 | (79.0-120.5) |  |  |  |  |  |  |
| Female | 102 | 101.2 | 100.8 | (82.2-122.4) |  | Female | 28 | 33.5 | 83.5 | (55.5-120.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 23 | 22.4 | 102.5 | (64.9-153.8) |  | Male | 25 | 29.5 | 84.8 | (54.8-125.1) |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 22 | 33.0 | 66.7 | (41.8-100.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 11 | 9.0 | 122.5 | (61.1-219.1) |  | Male | 223 | 287.8 | 77.5 | (67.6-88.3) |
| Female | 4 | 7.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 46 | 49.2 | 93.6 | (68.5-124.8) |  | Male | 24 | 19.9 | 120.7 | (77.3-179.6) |
| Female | 38 | 29.8 | 127.3 | (90.1-174.8) |  | Female | 28 | 13.0 | 215.4 | (143.1-311.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 13.3 | 142.5 | (85.8-222.6) |  | Male | 15 | 18.1 | 82.7 | (46.2-136.4) |
| Female | 8 | 4.3 | 186.0 | (80.1-366.4) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 32 | 36.4 | 87.8 | (60.1-124.0) |  | Male | 22 | 25.1 | 87.6 | (54.9-132.6) |
| Female | 41 | 29.1 | 140.8 | (101.0-191.0) |  | Female | 74 | 79.5 | 93.1 | (73.1-116.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 61 | 30.6 | 199.3 | (152.5-256.1) |  |  |  |  |  |  |
| Female | 7 | 10.6 | 66.2 | (26.5-136.5) |  | Female | 80 | 83.1 | 96.3 | (76.3-119.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 185 | 148.4 | 124.7 | (107.4-144.0) |  | Male | 1163 | 1142.6 | 101.8 | (96.0-107.8) |
| Female | 190 | 173.3 | 109.6 | (94.6-126.4) |  | Female | 1221 | 1276.9 | 95.6 | (90.3-101.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

169

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 26.1 | 111.3 | (74.5-159.8) |  | Male | 15 | 16.6 | 90.3 | (50.5-148.9) |
| Female | 6 | 10.2 | 58.9 | (21.5-128.2) |  | Female | 15 | 13.3 | 113.0 | (63.2-186.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 15 | 14.8 | 101.1 | (56.5-166.7) |
| Female | 79 | 106.0 | 74.5 | (59.0-92.9) |  | Female | 10 | 13.8 | 72.6 | (34.7-133.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 12.1 | 58.1 | (23.3-119.6) |
| Female | 5 | 3.3 | 149.4 | (48.1-348.6) |  | Female | 2 | 5.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 28.3 | 119.9 | (83.0-167.6) |  |  |  |  |  |  |
| Female | 25 | 30.3 | 82.5 | (53.4-121.7) |  | Female | 11 | 9.5 | 116.3 | (58.0-208.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.9 | nc | (nc-nc) |  | Male | 4 | 9.2 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 12 | 10.2 | 117.3 | (60.6-205.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 71 | 86.7 | 81.9 | (63.9-103.3) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 14.0 | 128.3 | (76.0-202.7) |  | Male | 7 | 6.1 | 114.7 | (45.9-236.3) |
| Female | 6 | 8.6 | 70.1 | (25.6-152.7) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 10.2 | 58.7 | (21.4-127.8) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 6 | 7.9 | 75.7 | (27.6-164.8) |  | Female | 5 | 17.8 | 28.2 | (9.1-65.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 9.0 | 89.1 | (38.4-175.5) |  |  |  |  |  |  |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 21 | 24.2 | 86.9 | (53.8-132.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 45.8 | 69.8 | (47.7-98.6) |  | Male | 290 | 338.9 | 85.6 | (76.0-96.0) |
| Female | 38 | 53.1 | 71.5 | (50.6-98.2) |  | Female | 284 | 364.2 | 78.0 | (69.2-87.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

170

# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 11.9 | 58.9 | (23.6-121.4) |  | Male | 6 | 7.7 | 77.5 | (28.3-168.6) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 2 | 5.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 6 | 2.5 | 242.9 | (88.7-528.7) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 7.0 | nc | (nc-nc) |
| Female | 56 | 47.6 | 117.6 | (88.9-152.8) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.8 | 85.8 | (27.7-200.2) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 13.3 | 120.2 | (68.6-195.1) |  |  |  |  |  |  |
| Female | 12 | 12.1 | 99.0 | (51.1-172.9) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 43 | 41.4 | 103.8 | (75.1-139.8) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.8 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 4.7 | 168.5 | (72.5-331.9) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 6 | 8.6 | 69.5 | (25.4-151.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 17 | 11.3 | 150.6 | (87.7-241.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 21.3 | 112.9 | (72.3-168.1) |  | Male | 156 | 159.4 | 97.9 | (83.1-114.5) |
| Female | 16 | 21.1 | 75.7 | (43.2-123.0) |  | Female | 148 | 156.1 | 94.8 | (80.1-111.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

171

# Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 65 | 71.2 | 91.2 | (70.4-116.3) |  | Male | 43 | 48.7 | 88.2 | (63.8-118.8) |
| Female | 24 | 29.4 | 81.6 | (52.3-121.4) |  | Female | 32 | 44.6 | 71.8 | (49.1-101.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 21 | 16.4 | 128.4 | (79.5-196.3) |  | Male | 26 | 14.9 | 174.7 | (114.1-256.0) |
| Female | 15 | 14.3 | 105.1 | (58.8-173.4) |  | Female | 13 | 13.3 | 98.0 | (52.1-167.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.5 | 199.1 | (64.2-464.7) |  | Male | 54 | 44.0 | 122.8 | (92.2-160.2) |
| Female | 319 | 332.7 | 95.9 | (85.6-107.0) |  | Female | 49 | 41.9 | 117.1 | (86.6-154.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 50 | 35.8 | 139.7 | (103.7-184.2) |
| Female | 17 | 12.2 | 139.8 | (81.4-223.9) |  | Female | 20 | 17.6 | 113.6 | (69.4-175.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 110 | 81.0 | 135.8 | (111.6-163.7) |  |  |  |  |  |  |
| Female | 109 | 90.1 | 121.0 | (99.4-146.0) |  | Female | 25 | 29.8 | 83.8 | (54.2-123.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 24 | 19.3 | 124.2 | (79.5-184.8) |  | Male | 23 | 25.5 | 90.2 | (57.2-135.4) |
| Female | 6 | 5.7 | 105.4 | (38.5-229.4) |  | Female | 24 | 29.4 | 81.6 | (52.3-121.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 7.2 | 69.2 | (22.3-161.5) |  | Male | 305 | 247.5 | 123.2 | (109.8-137.9) |
| Female | 2 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 41 | 42.3 | 96.9 | (69.5-131.5) |  | Male | 16 | 17.2 | 92.9 | (53.1-150.9) |
| Female | 23 | 26.5 | 86.7 | (54.9-130.1) |  | Female | 21 | 11.6 | 181.8 | (112.5-277.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 11.4 | 148.9 | (86.7-238.4) |  | Male | 17 | 14.2 | 119.6 | (69.6-191.5) |
| Female | 4 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 40 | 31.3 | 128.0 | (91.4-174.3) |  | Male | 17 | 21.1 | 80.5 | (46.9-129.0) |
| Female | 32 | 25.7 | 124.7 | (85.3-176.0) |  | Female | 53 | 68.3 | 77.6 | (58.1-101.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 56 | 26.0 | 215.1 | (162.5-279.4) |  |  |  |  |  |  |
| Female | 18 | 9.4 | 191.3 | (113.3-302.4) |  | Female | 71 | 74.1 | 95.8 | (74.8-120.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 195 | 128.1 | 152.2 | (131.6-175.1) |  | Male | 1231 | 982.5 | 125.3 | (118.4-132.5) |
| Female | 179 | 155.2 | 115.3 | (99.1-133.5) |  | Female | 1159 | 1132.6 | 102.3 | (96.5-108.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

172

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 15.9 | 94.3 | (52.7-155.5) |  | Male | 22 | 10.0 | 220.5 | (138.1-333.8) |
| Female | 9 | 5.0 | 178.5 | (81.4-338.9) |  | Female | 12 | 6.8 | 175.8 | (90.7-307.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 5 | 3.2 | 155.4 | (50.1-362.7) |
| Female | 5 | 2.1 | 233.7 | (75.3-545.3) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 14 | 8.8 | 158.8 | (86.8-266.5) |
| Female | 50 | 55.7 | 89.7 | (66.6-118.3) |  | Female | 15 | 6.9 | 216.2 | (120.9-356.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 7.0 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 16.8 | 77.5 | (41.2-132.5) |  |  |  |  |  |  |
| Female | 22 | 15.1 | 145.8 | (91.4-220.8) |  | Female | 7 | 4.9 | 143.5 | (57.5-295.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 6 | 5.5 | 108.9 | (39.8-237.1) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.0 | 119.6 | (43.7-260.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 46 | 51.6 | 89.1 | (65.2-118.8) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 8.3 | 131.9 | (65.8-236.1) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 5 | 1.6 | 320.6 | (103.3-748.2) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 6.1 | 165.0 | (79.0-303.4) |  | Male | 6 | 3.6 | 167.7 | (61.2-365.1) |
| Female | 5 | 4.0 | 125.9 | (40.6-293.9) |  | Female | 15 | 9.6 | 156.5 | (87.5-258.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 16 | 12.5 | 127.6 | (72.9-207.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 28.7 | 69.6 | (42.5-107.5) |  | Male | 200 | 203.0 | 98.5 | (85.4-113.2) |
| Female | 28 | 26.8 | 104.3 | (69.3-150.8) |  | Female | 221 | 186.8 | 118.3 | (103.2-135.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

173

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 48.6 | 55.5 | (36.6-80.8) |  | Male | 8 | 33.6 | 23.8 | (10.3-46.9) |
| Female | 26 | 19.3 | 134.8 | (88.0-197.5) |  | Female | 20 | 30.2 | 66.2 | (40.4-102.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 10.9 | nc | (nc-nc) |  | Male | 7 | 10.1 | 69.0 | (27.6-142.1) |
| Female | 8 | 9.4 | 85.5 | (36.8-168.4) |  | Female | 7 | 8.7 | 80.1 | (32.1-165.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 40 | 30.0 | 133.2 | (95.1-181.3) |
| Female | 193 | 221.6 | 87.1 | (75.2-100.3) |  | Female | 23 | 27.8 | 82.7 | (52.4-124.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 24.3 | 94.7 | (60.0-142.2) |
| Female | 13 | 8.5 | 153.4 | (81.6-262.3) |  | Female | 9 | 11.7 | 77.0 | (35.1-146.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 71 | 54.6 | 130.0 | (101.5-163.9) |  |  |  |  |  |  |
| Female | 79 | 59.9 | 131.8 | (104.3-164.2) |  | Female | 16 | 19.9 | 80.5 | (46.0-130.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 13.1 | 114.2 | (63.9-188.4) |  | Male | 21 | 17.3 | 121.2 | (75.0-185.3) |
| Female | 8 | 3.7 | 216.4 | (93.2-426.4) |  | Female | 15 | 19.3 | 77.7 | (43.5-128.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 129 | 165.3 | 78.0 | (65.1-92.7) |
| Female | 5 | 4.4 | 113.1 | (36.4-263.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 34 | 28.6 | 119.0 | (82.4-166.3) |  | Male | 15 | 11.7 | 127.8 | (71.5-210.8) |
| Female | 18 | 17.4 | 103.2 | (61.2-163.2) |  | Female | 6 | 7.7 | 78.1 | (28.5-170.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 7.7 | 142.3 | (70.9-254.6) |  | Male | 8 | 10.8 | 73.8 | (31.8-145.4) |
| Female | 5 | 2.5 | 196.7 | (63.4-458.9) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 24 | 20.9 | 114.7 | (73.5-170.7) |  | Male | 15 | 14.8 | 101.4 | (56.7-167.2) |
| Female | 16 | 16.7 | 95.7 | (54.7-155.5) |  | Female | 62 | 47.7 | 129.9 | (99.6-166.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 24 | 17.7 | 135.5 | (86.8-201.7) |  |  |  |  |  |  |
| Female | 13 | 6.2 | 211.0 | (112.2-360.8) |  | Female | 51 | 48.8 | 104.4 | (77.7-137.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 117 | 86.9 | 134.6 | (111.3-161.3) |  | Male | 639 | 666.6 | 95.9 | (88.6-103.6) |
| Female | 111 | 100.7 | 110.3 | (90.7-132.8) |  | Female | 772 | 752.3 | 102.6 | (95.5-110.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

174

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 8.1 | nc | (nc-nc) |  | Male | 14 | 4.7 | 295.1 | (161.2-495.2) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 3.3 | 150.1 | (48.4-350.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 32 | 27.7 | 115.6 | (79.0-163.2) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 8.3 | 59.9 | (19.3-139.8) |  |  |  |  |  |  |
| Female | 5 | 7.5 | 66.8 | (21.5-155.8) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.7 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 28 | 22.9 | 122.5 | (81.4-177.1) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 9 | 4.4 | 203.1 | (92.7-385.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 8 | 6.3 | 126.8 | (54.6-249.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 13.7 | 43.9 | (16.0-95.5) |  | Male | 89 | 96.1 | 92.6 | (74.4-114.0) |
| Female | 10 | 14.1 | 71.0 | (34.0-130.7) |  | Female | 95 | 93.3 | 101.8 | (82.4-124.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

175

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 15.6 | 128.2 | (78.3-197.9) |  | Male | 26 | 11.6 | 223.6 | (146.0-327.6) |
| Female | 0 | 5.6 | nc | (nc-nc) |  | Female | 20 | 10.3 | 193.6 | (118.2-299.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 4.1 | 193.7 | (83.4-381.6) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 7 | 3.3 | 214.9 | (86.1-442.8) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 14 | 10.6 | 132.6 | (72.5-222.6) |
| Female | 89 | 80.2 | 110.9 | (89.1-136.5) |  | Female | 4 | 8.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.2 | 119.5 | (59.6-213.9) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 19.3 | 140.0 | (92.2-203.7) |  |  |  |  |  |  |
| Female | 28 | 18.5 | 151.6 | (100.7-219.2) |  | Female | 7 | 6.9 | 102.0 | (40.8-210.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 4 | 5.8 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 9 | 5.5 | 162.6 | (74.2-308.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 57 | 58.5 | 97.4 | (73.7-126.1) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 10.5 | 132.9 | (72.6-222.9) |  | Male | 6 | 4.0 | 150.6 | (55.0-327.8) |
| Female | 9 | 5.9 | 153.6 | (70.1-291.6) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 6 | 3.5 | 170.0 | (62.1-370.1) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.4 | 121.6 | (55.5-230.8) |  | Male | 16 | 5.6 | 284.1 | (162.3-461.4) |
| Female | 10 | 5.3 | 188.5 | (90.2-346.7) |  | Female | 19 | 17.9 | 106.3 | (64.0-166.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.5 | 92.4 | (33.7-201.2) |  |  |  |  |  |  |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 14 | 17.4 | 80.3 | (43.9-134.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 28.6 | 112.1 | (76.6-158.2) |  | Male | 279 | 231.9 | 120.3 | (106.6-135.3) |
| Female | 38 | 30.2 | 125.8 | (89.0-172.7) |  | Female | 290 | 251.3 | 115.4 | (102.5-129.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

176

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 24.9 | 96.5 | (61.8-143.5) |  | Male | 38 | 15.5 | 244.7 | (173.1-335.8) |
| Female | 13 | 8.8 | 147.7 | (78.6-252.7) |  | Female | 22 | 12.1 | 181.3 | (113.6-274.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 4.4 | nc | (nc-nc) |  | Male | 8 | 5.0 | 160.9 | (69.3-317.1) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 8 | 4.0 | 200.1 | (86.2-394.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 13 | 13.9 | 93.9 | (49.9-160.5) |
| Female | 122 | 99.4 | 122.7 | (101.9-146.6) |  | Female | 11 | 12.3 | 89.8 | (44.7-160.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 11.0 | 99.6 | (49.7-178.3) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 6 | 5.3 | 114.1 | (41.7-248.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 26.2 | 122.0 | (83.4-172.2) |  |  |  |  |  |  |
| Female | 17 | 26.4 | 64.3 | (37.5-103.0) |  | Female | 6 | 8.8 | 68.5 | (25.0-149.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.5 | 92.7 | (33.8-201.7) |  | Male | 13 | 8.6 | 150.4 | (80.0-257.1) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 14 | 8.8 | 159.2 | (86.9-267.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 96 | 81.0 | 118.5 | (96.0-144.8) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 13.2 | 83.6 | (41.7-149.5) |  | Male | 7 | 5.8 | 121.3 | (48.6-250.0) |
| Female | 5 | 7.8 | 63.9 | (20.6-149.2) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 9.7 | 113.9 | (56.8-203.8) |  | Male | 9 | 5.6 | 160.0 | (73.0-303.8) |
| Female | 10 | 7.1 | 141.6 | (67.8-260.4) |  | Female | 17 | 17.1 | 99.6 | (58.0-159.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 8.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 20 | 22.9 | 87.3 | (53.3-134.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 44.4 | 56.3 | (36.4-83.1) |  | Male | 338 | 317.6 | 106.4 | (95.4-118.4) |
| Female | 38 | 47.0 | 80.9 | (57.3-111.1) |  | Female | 360 | 331.2 | 108.7 | (97.8-120.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

177

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 7.2 | nc | (nc-nc) |  | Male | 8 | 4.5 | 179.7 | (77.4-354.0) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.0 | 201.9 | (86.9-397.9) |
| Female | 33 | 26.2 | 126.1 | (86.8-177.0) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 7.5 | 107.3 | (46.2-211.5) |  |  |  |  |  |  |
| Female | 10 | 8.6 | 115.8 | (55.4-213.0) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 23 | 27.0 | 85.1 | (54.0-127.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 2.7 | 368.9 | (176.6-678.5) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 6 | 6.1 | 98.5 | (36.0-214.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 13.0 | 61.3 | (26.4-120.9) |  | Male | 86 | 95.3 | 90.2 | (72.2-111.4) |
| Female | 18 | 13.4 | 134.3 | (79.6-212.3) |  | Female | 101 | 94.2 | 107.2 | (87.3-130.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

178

# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 38.1 | 104.9 | (74.9-142.8) |  | Male | 25 | 25.6 | 97.7 | (63.2-144.3) |
| Female | 9 | 13.3 | 67.9 | (31.0-128.9) |  | Female | 15 | 20.1 | 74.7 | (41.8-123.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 8.0 | 74.7 | (27.3-162.6) |  | Male | 5 | 7.9 | 63.1 | (20.3-147.2) |
| Female | 8 | 6.2 | 128.5 | (55.3-253.3) |  | Female | 5 | 6.0 | 82.8 | (26.7-193.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 19 | 22.8 | 83.3 | (50.1-130.1) |
| Female | 140 | 154.0 | 90.9 | (76.5-107.3) |  | Female | 17 | 19.0 | 89.3 | (52.0-143.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 18.5 | 97.2 | (57.6-153.6) |
| Female | 9 | 5.6 | 159.9 | (73.0-303.6) |  | Female | 18 | 8.0 | 224.3 | (132.9-354.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 46 | 42.4 | 108.5 | (79.4-144.7) |  |  |  |  |  |  |
| Female | 61 | 40.9 | 149.1 | (114.0-191.5) |  | Female | 16 | 13.5 | 118.3 | (67.6-192.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 10.2 | 117.5 | (60.6-205.2) |  | Male | 9 | 13.5 | 66.8 | (30.5-126.8) |
| Female | 5 | 2.6 | 194.6 | (62.7-454.0) |  | Female | 14 | 13.3 | 105.5 | (57.6-177.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.3 | 181.9 | (66.4-396.0) |  | Male | 128 | 126.9 | 100.9 | (84.1-119.9) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 21.8 | 114.5 | (74.0-169.0) |  | Male | 7 | 9.1 | 76.9 | (30.8-158.5) |
| Female | 10 | 12.1 | 82.8 | (39.6-152.2) |  | Female | 6 | 5.2 | 115.1 | (42.0-250.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 6.0 | 100.5 | (36.7-218.8) |  | Male | 2 | 6.4 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 16.1 | 105.9 | (61.6-169.5) |  | Male | 10 | 10.6 | 94.8 | (45.4-174.3) |
| Female | 12 | 11.3 | 106.6 | (55.0-186.3) |  | Female | 38 | 30.8 | 123.5 | (87.4-169.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 13.7 | 80.1 | (40.0-143.4) |  |  |  |  |  |  |
| Female | 7 | 4.3 | 163.3 | (65.4-336.4) |  | Female | 37 | 34.5 | 107.4 | (75.6-148.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 48 | 68.4 | 70.1 | (51.7-93.0) |  | Male | 478 | 511.1 | 93.5 | (85.3-102.3) |
| Female | 71 | 70.0 | 101.4 | (79.2-127.9) |  | Female | 551 | 515.7 | 106.8 | (98.1-116.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

179

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 26.4 | 83.2 | (52.1-126.0) |  | Male | 32 | 17.7 | 180.8 | (123.6-255.2) |
| Female | 11 | 9.2 | 119.8 | (59.7-214.3) |  | Female | 27 | 14.2 | 190.1 | (125.3-276.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 5.5 | 164.1 | (74.9-311.4) |  | Male | 10 | 5.6 | 179.5 | (85.9-330.0) |
| Female | 6 | 4.4 | 135.7 | (49.6-295.4) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 11 | 15.9 | 69.1 | (34.4-123.6) |
| Female | 139 | 116.3 | 119.5 | (100.5-141.1) |  | Female | 9 | 13.6 | 66.1 | (30.2-125.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 14.0 | 71.4 | (34.2-131.4) |
| Female | 5 | 3.9 | 127.1 | (41.0-296.7) |  | Female | 5 | 5.9 | 84.5 | (27.2-197.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 29.9 | 83.5 | (54.0-123.2) |  |  |  |  |  |  |
| Female | 29 | 27.7 | 104.6 | (70.0-150.2) |  | Female | 12 | 10.1 | 119.2 | (61.5-208.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.6 | 65.8 | (21.2-153.5) |  | Male | 13 | 9.8 | 132.9 | (70.7-227.2) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 13 | 9.2 | 142.0 | (75.5-242.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 119 | 102.3 | 116.4 | (96.4-139.3) |
| Female | 4 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 16.0 | 143.6 | (91.0-215.5) |  | Male | 6 | 6.4 | 93.3 | (34.1-203.1) |
| Female | 6 | 8.9 | 67.7 | (24.7-147.4) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 10.9 | 109.7 | (56.6-191.6) |  | Male | 7 | 7.3 | 95.7 | (38.3-197.1) |
| Female | 3 | 7.6 | nc | (nc-nc) |  | Female | 25 | 21.4 | 116.6 | (75.5-172.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 10.2 | 117.4 | (60.6-205.0) |  |  |  |  |  |  |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 21 | 27.4 | 76.7 | (47.5-117.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 48.4 | 93.0 | (67.8-124.5) |  | Male | 389 | 372.1 | 104.5 | (94.4-115.5) |
| Female | 59 | 51.7 | 114.1 | (86.9-147.2) |  | Female | 407 | 374.9 | 108.6 | (98.3-119.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

180

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 22.7 | 118.9 | (78.3-173.0) |  | Male | 16 | 13.4 | 119.4 | (68.2-193.8) |
| Female | 8 | 8.7 | 91.8 | (39.5-181.0) |  | Female | 20 | 10.3 | 193.4 | (118.1-298.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 5 | 4.4 | 114.0 | (36.8-266.1) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 17 | 11.8 | 144.2 | (83.9-230.8) |
| Female | 80 | 84.0 | 95.2 | (75.5-118.5) |  | Female | 16 | 11.3 | 141.7 | (80.9-230.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 8.8 | 135.7 | (70.0-237.1) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 22.5 | 80.0 | (47.4-126.4) |  |  |  |  |  |  |
| Female | 25 | 24.6 | 101.8 | (65.9-150.3) |  | Female | 7 | 7.6 | 92.1 | (36.9-189.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.6 | 88.5 | (28.5-206.6) |  | Male | 9 | 7.6 | 117.7 | (53.7-223.4) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 8 | 8.6 | 93.1 | (40.1-183.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 79 | 69.3 | 114.0 | (90.3-142.1) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.8 | 120.3 | (64.0-205.7) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 8 | 7.1 | 112.6 | (48.5-221.9) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 4 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.2 | 60.7 | (19.5-141.6) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 10 | 6.4 | 156.5 | (74.9-287.7) |  | Female | 9 | 12.4 | 72.6 | (33.1-137.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.9 | 86.6 | (31.6-188.6) |  |  |  |  |  |  |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 16 | 19.8 | 80.8 | (46.1-131.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 40.4 | 84.1 | (58.2-117.5) |  | Male | 285 | 274.1 | 104.0 | (92.2-116.8) |
| Female | 50 | 47.0 | 106.3 | (78.9-140.1) |  | Female | 299 | 295.9 | 101.1 | (89.9-113.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

181

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 7.8 | 128.2 | (61.4-235.9) |  | Male | 7 | 4.9 | 142.7 | (57.2-294.1) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 6 | 3.6 | 167.2 | (61.1-364.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 45 | 29.9 | 150.5 | (109.8-201.4) |  | Female | 5 | 3.7 | 136.2 | (43.9-317.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 3.4 | 323.9 | (161.4-579.5) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 8.0 | 125.0 | (59.8-229.8) |  |  |  |  |  |  |
| Female | 11 | 7.7 | 143.1 | (71.3-256.1) |  | Female | 6 | 2.6 | 231.2 | (84.4-503.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 44 | 26.1 | 168.8 | (122.6-226.6) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 12 | 6.9 | 173.7 | (89.7-303.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 14.5 | 110.4 | (63.1-179.4) |  | Male | 129 | 100.3 | 128.6 | (107.3-152.8) |
| Female | 12 | 14.6 | 82.0 | (42.3-143.3) |  | Female | 122 | 99.2 | 122.9 | (102.1-146.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

182

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 11.5 | 112.8 | (60.0-192.9) |  | Male | 7 | 7.4 | 94.7 | (37.9-195.1) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 6 | 5.5 | 108.4 | (39.6-236.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 8 | 6.6 | 120.6 | (51.9-237.6) |
| Female | 49 | 42.4 | 115.6 | (85.5-152.8) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.3 | 93.7 | (30.2-218.6) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 12.5 | 144.5 | (85.6-228.4) |  |  |  |  |  |  |
| Female | 19 | 11.1 | 171.6 | (103.3-268.0) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.6 | 138.8 | (44.7-323.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 29 | 38.0 | 76.2 | (51.1-109.5) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.3 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 5 | 3.3 | 151.3 | (48.8-353.1) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 5 | 3.1 | 162.7 | (52.4-379.6) |  | Female | 10 | 8.5 | 117.3 | (56.2-215.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 5 | 9.7 | 51.7 | (16.7-120.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 20.4 | 44.1 | (20.1-83.7) |  | Male | 126 | 150.4 | 83.8 | (69.8-99.7) |
| Female | 19 | 18.8 | 101.2 | (60.9-158.0) |  | Female | 154 | 141.1 | 109.2 | (92.6-127.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

183

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 13.2 | 60.7 | (26.1-119.5) |  | Male | 10 | 8.7 | 115.6 | (55.3-212.5) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 9 | 6.2 | 146.0 | (66.6-277.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 4 | 1.9 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 3 | 7.8 | nc | (nc-nc) |
| Female | 54 | 49.8 | 108.4 | (81.4-141.4) |  | Female | 5 | 5.7 | 87.4 | (28.2-203.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.6 | 106.3 | (42.6-219.0) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 14.7 | 95.0 | (51.9-159.5) |  |  |  |  |  |  |
| Female | 13 | 12.5 | 104.2 | (55.4-178.2) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 59 | 46.2 | 127.8 | (97.3-164.9) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.5 | 79.7 | (29.1-173.4) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.4 | 111.4 | (40.7-242.5) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 8 | 3.3 | 240.4 | (103.5-473.7) |  | Female | 9 | 9.5 | 94.4 | (43.1-179.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 9 | 11.3 | 79.9 | (36.5-151.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 23.4 | 47.1 | (23.5-84.2) |  | Male | 151 | 177.7 | 85.0 | (72.0-99.7) |
| Female | 14 | 20.3 | 69.0 | (37.7-115.8) |  | Female | 152 | 159.5 | 95.3 | (80.7-111.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

184

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 63 | 57.2 | 110.1 | (84.6-140.8) |  | Male | 25 | 36.5 | 68.4 | (44.3-101.0) |
| Female | 21 | 22.5 | 93.2 | (57.7-142.5) |  | Female | 25 | 32.1 | 77.9 | (50.4-115.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 11.0 | 109.6 | (56.6-191.4) |  | Male | 10 | 11.3 | 88.8 | (42.5-163.3) |
| Female | 11 | 9.7 | 112.9 | (56.3-202.0) |  | Female | 11 | 10.0 | 109.5 | (54.6-196.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 29 | 32.6 | 88.8 | (59.5-127.6) |
| Female | 243 | 237.4 | 102.4 | (89.9-116.1) |  | Female | 22 | 31.3 | 70.4 | (44.1-106.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 24.7 | 133.8 | (92.1-187.9) |
| Female | 7 | 8.4 | 82.9 | (33.2-170.9) |  | Female | 14 | 12.9 | 108.2 | (59.1-181.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 72 | 60.9 | 118.2 | (92.5-148.8) |  |  |  |  |  |  |
| Female | 81 | 67.4 | 120.2 | (95.5-149.4) |  | Female | 25 | 21.5 | 116.3 | (75.3-171.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 14.3 | 90.7 | (48.2-155.1) |  | Male | 18 | 19.6 | 91.8 | (54.4-145.1) |
| Female | 7 | 4.3 | 161.8 | (64.8-333.3) |  | Female | 13 | 22.6 | 57.6 | (30.7-98.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 5.0 | 99.5 | (32.1-232.3) |  | Male | 155 | 174.1 | 89.0 | (75.6-104.2) |
| Female | 5 | 4.4 | 112.9 | (36.4-263.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 29.6 | 91.2 | (60.1-132.6) |  | Male | 16 | 13.2 | 120.9 | (69.0-196.3) |
| Female | 24 | 19.2 | 124.7 | (79.9-185.5) |  | Female | 9 | 8.7 | 103.6 | (47.3-196.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 8.3 | 120.5 | (57.7-221.7) |  | Male | 13 | 10.0 | 130.2 | (69.3-222.7) |
| Female | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 23.0 | 117.6 | (77.5-171.1) |  | Male | 12 | 14.1 | 85.1 | (43.9-148.6) |
| Female | 25 | 18.3 | 137.0 | (88.6-202.2) |  | Female | 46 | 46.7 | 98.5 | (72.1-131.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 18.5 | 102.7 | (61.8-160.3) |  |  |  |  |  |  |
| Female | 8 | 7.1 | 113.2 | (48.8-223.1) |  | Female | 56 | 53.8 | 104.2 | (78.7-135.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 101 | 99.8 | 101.2 | (82.4-122.9) |  | Male | 717 | 725.2 | 98.9 | (91.8-106.4) |
| Female | 135 | 117.6 | 114.8 | (96.2-135.9) |  | Female | 867 | 826.2 | 104.9 | (98.1-112.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

185

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 11.9 | 117.4 | (64.2-197.1) |  | Male | 7 | 8.1 | 86.7 | (34.7-178.6) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.5 | (23.7-171.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 12 | 7.3 | 164.0 | (84.7-286.6) |
| Female | 54 | 53.4 | 101.1 | (75.9-131.9) |  | Female | 6 | 6.4 | 94.5 | (34.5-205.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 13.7 | 124.1 | (72.3-198.8) |  |  |  |  |  |  |
| Female | 16 | 14.2 | 112.8 | (64.4-183.1) |  | Female | 6 | 4.7 | 127.0 | (46.4-276.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 3.4 | 206.1 | (82.6-424.6) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 43 | 44.7 | 96.2 | (69.6-129.6) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 7.3 | 68.7 | (22.1-160.2) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 0 | 4.1 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 12 | 10.5 | 114.6 | (59.1-200.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 10 | 11.8 | 84.4 | (40.4-155.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 21.7 | 64.6 | (35.3-108.5) |  | Male | 153 | 167.7 | 91.2 | (77.4-106.9) |
| Female | 25 | 22.3 | 112.3 | (72.6-165.7) |  | Female | 161 | 174.9 | 92.0 | (78.4-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

186

# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 28.4 | 81.1 | (51.4-121.7) |  | Male | 22 | 18.6 | 118.4 | (74.2-179.3) |
| Female | 13 | 11.2 | 116.0 | (61.7-198.3) |  | Female | 21 | 15.8 | 133.1 | (82.4-203.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.6 | 88.5 | (28.5-206.6) |  | Male | 5 | 5.8 | 86.2 | (27.8-201.2) |
| Female | 7 | 4.8 | 144.6 | (57.9-298.0) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 20 | 16.6 | 120.4 | (73.5-186.0) |
| Female | 124 | 120.5 | 102.9 | (85.6-122.7) |  | Female | 16 | 15.6 | 102.7 | (58.6-166.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 13.3 | 97.9 | (52.1-167.4) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 5 | 6.5 | 76.5 | (24.7-178.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 46 | 31.0 | 148.2 | (108.5-197.6) |  |  |  |  |  |  |
| Female | 35 | 34.6 | 101.3 | (70.5-140.8) |  | Female | 10 | 10.8 | 92.4 | (44.2-169.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 7.5 | 160.0 | (82.6-279.5) |  | Male | 12 | 10.0 | 120.3 | (62.1-210.1) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 16 | 11.5 | 139.6 | (79.8-226.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 91 | 94.7 | 96.1 | (77.3-118.0) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 16.0 | 87.5 | (47.8-146.7) |  | Male | 5 | 6.7 | 74.8 | (24.1-174.5) |
| Female | 10 | 9.6 | 104.6 | (50.1-192.4) |  | Female | 5 | 4.5 | 111.8 | (36.0-260.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 4.3 | 207.0 | (94.4-392.9) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 11.6 | 164.2 | (98.8-256.4) |  | Male | 9 | 7.6 | 119.2 | (54.4-226.2) |
| Female | 9 | 9.2 | 97.9 | (44.7-185.9) |  | Female | 25 | 22.6 | 110.6 | (71.6-163.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 9.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 31 | 27.1 | 114.4 | (77.7-162.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 50 | 50.7 | 98.6 | (73.2-130.0) |  | Male | 397 | 374.8 | 105.9 | (95.8-116.9) |
| Female | 46 | 56.7 | 81.1 | (59.4-108.2) |  | Female | 419 | 413.3 | 101.4 | (91.9-111.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

187

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 6.9 | nc | (nc-nc) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 21 | 22.9 | 91.7 | (56.7-140.2) |  | Female | 7 | 2.5 | 281.8 | (112.9-580.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 7.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 5.0 | 99.2 | (32.0-231.6) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 24 | 22.4 | 107.2 | (68.7-159.6) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 2.7 | 219.8 | (80.2-478.4) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 7 | 5.1 | 137.0 | (54.9-282.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 11.5 | nc | (nc-nc) |  | Male | 58 | 88.6 | 65.4 | (49.7-84.6) |
| Female | 7 | 8.8 | 79.1 | (31.7-163.1) |  | Female | 77 | 70.5 | 109.2 | (86.2-136.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

188

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 6.7 | 75.0 | (24.2-175.1) |  | Male | 5 | 4.5 | 112.2 | (36.2-261.9) |
| Female | 5 | 2.3 | 220.3 | (71.0-514.2) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 20 | 29.2 | 68.5 | (41.8-105.8) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.4 | 121.1 | (55.2-229.8) |  |  |  |  |  |  |
| Female | 8 | 7.1 | 113.3 | (48.8-223.3) |  | Female | 5 | 2.5 | 197.2 | (63.5-460.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 21 | 24.4 | 86.0 | (53.2-131.5) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 5 | 2.2 | 226.6 | (73.0-528.9) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 12.3 | 81.6 | (39.1-150.0) |  | Male | 87 | 91.7 | 94.9 | (76.0-117.0) |
| Female | 20 | 12.7 | 157.4 | (96.1-243.1) |  | Female | 98 | 93.6 | 104.7 | (85.0-127.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

189

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 48 | 45.9 | 104.6 | (77.1-138.6) |  | Male | 24 | 30.6 | 78.5 | (50.3-116.9) |
| Female | 25 | 18.8 | 132.9 | (86.0-196.1) |  | Female | 25 | 26.4 | 94.7 | (61.3-139.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 9.6 | 125.1 | (64.5-218.5) |  | Male | 10 | 9.5 | 104.8 | (50.2-192.8) |
| Female | 13 | 8.2 | 157.9 | (84.0-270.0) |  | Female | 8 | 8.4 | 95.0 | (40.9-187.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 29 | 27.4 | 105.8 | (70.8-151.9) |
| Female | 188 | 205.9 | 91.3 | (78.7-105.3) |  | Female | 25 | 26.1 | 95.6 | (61.9-141.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 22.7 | 79.2 | (46.9-125.1) |
| Female | 8 | 7.1 | 113.4 | (48.8-223.4) |  | Female | 6 | 11.0 | 54.8 | (20.0-119.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 48 | 51.0 | 94.1 | (69.4-124.8) |  |  |  |  |  |  |
| Female | 55 | 57.1 | 96.4 | (72.6-125.4) |  | Female | 11 | 18.2 | 60.3 | (30.1-107.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 12.6 | 55.7 | (22.3-114.8) |  | Male | 17 | 16.5 | 103.1 | (60.0-165.1) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 18 | 18.9 | 95.4 | (56.5-150.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.8 | 158.2 | (57.8-344.2) |  | Male | 171 | 162.5 | 105.2 | (90.0-122.2) |
| Female | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 26.6 | 82.6 | (51.8-125.1) |  | Male | 14 | 11.0 | 127.2 | (69.5-213.4) |
| Female | 19 | 16.4 | 115.9 | (69.7-180.9) |  | Female | 5 | 7.3 | 68.2 | (22.0-159.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 7.4 | 94.5 | (37.9-194.8) |  | Male | 11 | 6.9 | 158.8 | (79.2-284.2) |
| Female | 4 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 24 | 19.2 | 125.3 | (80.2-186.4) |  | Male | 17 | 12.5 | 135.5 | (78.9-217.0) |
| Female | 19 | 15.3 | 123.8 | (74.5-193.4) |  | Female | 37 | 38.2 | 96.9 | (68.2-133.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 16.8 | 89.1 | (49.8-147.0) |  |  |  |  |  |  |
| Female | 5 | 5.9 | 84.8 | (27.3-198.0) |  | Female | 47 | 46.0 | 102.3 | (75.1-136.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 99 | 83.0 | 119.3 | (97.0-145.3) |  | Male | 643 | 625.4 | 102.8 | (95.0-111.1) |
| Female | 121 | 98.8 | 122.5 | (101.6-146.4) |  | Female | 708 | 699.9 | 101.2 | (93.8-108.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

190

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 24.0 | 120.9 | (80.9-173.6) |  | Male | 21 | 16.0 | 131.3 | (81.2-200.7) |
| Female | 13 | 8.1 | 159.8 | (85.0-273.2) |  | Female | 13 | 12.5 | 104.4 | (55.5-178.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.0 | 100.6 | (32.4-234.8) |  | Male | 5 | 5.0 | 99.5 | (32.1-232.3) |
| Female | 5 | 3.9 | 129.7 | (41.8-302.7) |  | Female | 7 | 3.8 | 185.8 | (74.4-382.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 14 | 14.3 | 98.0 | (53.5-164.5) |
| Female | 115 | 99.2 | 116.0 | (95.8-139.2) |  | Female | 9 | 11.8 | 76.5 | (34.9-145.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 12.1 | 82.6 | (39.6-152.0) |
| Female | 5 | 3.4 | 146.8 | (47.3-342.6) |  | Female | 9 | 5.1 | 177.3 | (80.9-336.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 26.6 | 146.4 | (104.1-200.2) |  |  |  |  |  |  |
| Female | 29 | 24.7 | 117.4 | (78.6-168.6) |  | Female | 10 | 8.7 | 115.0 | (55.1-211.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.8 | 88.7 | (32.4-193.0) |  | Male | 13 | 8.7 | 149.5 | (79.5-255.6) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 6 | 8.1 | 73.7 | (26.9-160.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 99 | 91.7 | 107.9 | (87.7-131.4) |
| Female | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 14.4 | 118.3 | (68.9-189.4) |  | Male | 6 | 5.8 | 104.2 | (38.1-226.9) |
| Female | 3 | 7.6 | nc | (nc-nc) |  | Female | 0 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 5 | 3.3 | 150.7 | (48.6-351.8) |
| Female | 5 | 1.2 | 422.8 | (136.3-986.7) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 9.9 | 121.4 | (62.6-212.0) |  | Male | 8 | 6.5 | 122.4 | (52.7-241.2) |
| Female | 17 | 6.8 | 249.8 | (145.4-399.9) |  | Female | 26 | 18.8 | 138.0 | (90.1-202.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 8.8 | 158.6 | (86.6-266.2) |  |  |  |  |  |  |
| Female | 7 | 2.7 | 261.3 | (104.7-538.4) |  | Female | 30 | 22.8 | 131.6 | (88.8-187.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 44.6 | 105.4 | (77.5-140.2) |  | Male | 378 | 334.6 | 113.0 | (101.9-125.0) |
| Female | 69 | 44.4 | 155.5 | (121.0-196.7) |  | Female | 408 | 324.4 | 125.8 | (113.9-138.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

191

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 8 | 12.2 | 65.4 | (28.1-128.8) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 7 | 8.4 | 83.2 | (33.4-171.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

192

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 10.2 | 147.1 | (82.3-242.7) |  | Male | 8 | 7.2 | 110.9 | (47.8-218.6) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 5 | 3.8 | 130.7 | (42.1-304.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 10 | 6.4 | 155.2 | (74.3-285.4) |
| Female | 36 | 31.4 | 114.5 | (80.2-158.6) |  | Female | 7 | 3.7 | 188.9 | (75.7-389.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.6 | 88.5 | (28.5-206.6) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 11.8 | 93.3 | (46.5-167.0) |  |  |  |  |  |  |
| Female | 13 | 7.6 | 171.0 | (91.0-292.5) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 42 | 40.5 | 103.6 | (74.7-140.1) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.5 | nc | (nc-nc) |  | Male | 5 | 2.5 | 197.6 | (63.7-461.2) |
| Female | 5 | 2.4 | 207.2 | (66.8-483.5) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.4 | 114.8 | (37.0-267.8) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 6 | 5.8 | 103.6 | (37.8-225.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 8 | 7.3 | 109.3 | (47.0-215.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 18.9 | 95.0 | (56.3-150.2) |  | Male | 159 | 148.6 | 107.0 | (91.0-125.0) |
| Female | 19 | 14.2 | 134.1 | (80.7-209.4) |  | Female | 126 | 101.9 | 123.7 | (103.0-147.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

193

# Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 48 | 26.1 | 183.8 | (135.5-243.7) |  | Male | 10 | 17.5 | 57.2 | (27.4-105.3) |
| Female | 13 | 9.3 | 139.1 | (74.0-237.9) |  | Female | 16 | 14.2 | 113.0 | (64.5-183.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 7 | 4.3 | 164.7 | (66.0-339.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 19 | 15.7 | 120.7 | (72.6-188.5) |
| Female | 99 | 108.7 | 91.1 | (74.1-110.9) |  | Female | 22 | 13.5 | 163.5 | (102.5-247.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 12.9 | 93.2 | (48.1-162.9) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 6 | 5.7 | 105.8 | (38.6-230.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 29.5 | 98.3 | (65.8-141.2) |  |  |  |  |  |  |
| Female | 35 | 28.9 | 120.9 | (84.2-168.2) |  | Female | 10 | 9.6 | 104.4 | (50.0-192.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.0 | 128.6 | (58.7-244.2) |  | Male | 7 | 9.3 | 74.9 | (30.0-154.3) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 6 | 9.4 | 63.7 | (23.3-138.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 115 | 89.0 | 129.3 | (106.7-155.2) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 15.1 | 92.6 | (50.6-155.4) |  | Male | 14 | 6.3 | 223.1 | (121.9-374.4) |
| Female | 10 | 8.5 | 117.9 | (56.4-216.8) |  | Female | 1 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.1 | 99.4 | (49.6-177.9) |  | Male | 3 | 7.3 | nc | (nc-nc) |
| Female | 12 | 8.0 | 149.5 | (77.2-261.2) |  | Female | 19 | 21.6 | 88.0 | (52.9-137.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 9.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 26 | 24.2 | 107.5 | (70.2-157.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 46.5 | 90.4 | (65.1-122.2) |  | Male | 379 | 352.9 | 107.4 | (96.9-118.8) |
| Female | 65 | 49.2 | 132.1 | (101.9-168.3) |  | Female | 388 | 363.9 | 106.6 | (96.3-117.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

194

# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 14.7 | 95.1 | (52.0-159.6) |  | Male | 4 | 9.7 | nc | (nc-nc) |
| Female | 4 | 5.3 | nc | (nc-nc) |  | Female | 5 | 7.6 | 65.5 | (21.1-152.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 5 | 3.0 | 164.9 | (53.1-384.8) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 6 | 2.4 | 248.7 | (90.8-541.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 14 | 8.6 | 161.9 | (88.5-271.7) |
| Female | 59 | 60.3 | 97.8 | (74.5-126.2) |  | Female | 3 | 7.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.2 | 138.7 | (66.4-255.0) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 16.1 | 49.8 | (21.5-98.2) |  |  |  |  |  |  |
| Female | 13 | 15.9 | 81.8 | (43.5-139.9) |  | Female | 6 | 5.3 | 112.9 | (41.2-245.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.1 | 147.5 | (53.9-321.1) |  | Male | 6 | 5.3 | 113.0 | (41.3-245.9) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 11 | 5.2 | 210.1 | (104.7-375.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 61 | 54.1 | 112.8 | (86.3-144.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 8.6 | 150.9 | (80.3-258.1) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 7 | 4.8 | 146.8 | (58.8-302.4) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.9 | 101.0 | (36.9-219.8) |  | Male | 7 | 3.9 | 179.5 | (71.9-369.8) |
| Female | 6 | 4.3 | 139.3 | (50.9-303.3) |  | Female | 8 | 11.3 | 70.7 | (30.4-139.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 5.2 | 135.8 | (54.4-279.8) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 10 | 13.8 | 72.4 | (34.6-133.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 27.1 | 165.9 | (121.0-222.0) |  | Male | 234 | 200.5 | 116.7 | (102.2-132.6) |
| Female | 32 | 28.3 | 113.2 | (77.4-159.9) |  | Female | 201 | 201.8 | 99.6 | (86.3-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

195

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 6.7 | 164.9 | (82.2-295.0) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 5 | 4.3 | 116.5 | (37.5-271.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.4 | 114.7 | (37.0-267.7) |
| Female | 33 | 34.1 | 96.7 | (66.6-135.8) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.0 | 150.3 | (54.9-327.1) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 8.3 | 108.4 | (49.5-205.8) |  |  |  |  |  |  |
| Female | 12 | 8.6 | 140.2 | (72.3-244.9) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 35 | 26.8 | 130.4 | (90.8-181.3) |
| Female | 3 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 4.5 | 155.1 | (62.1-319.5) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 16 | 6.5 | 245.2 | (140.1-398.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 6 | 7.8 | 77.1 | (28.2-167.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 12.8 | 93.8 | (48.4-163.9) |  | Male | 119 | 100.2 | 118.8 | (98.4-142.1) |
| Female | 15 | 15.4 | 97.7 | (54.6-161.2) |  | Female | 120 | 111.8 | 107.4 | (89.0-128.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

196

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 10 | 11.1 | 90.4 | (43.3-166.2) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 11 | 7.7 | 142.8 | (71.2-255.6) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 35 | 29.3 | 119.5 | (83.2-166.1) |
| Female | 9 | 4.4 | 205.1 | (93.6-389.3) |  | Female | 33 | 34.9 | 94.6 | (65.1-132.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

197

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 26.1 | 76.7 | (46.9-118.5) |  | Male | 30 | 16.8 | 179.0 | (120.8-255.6) |
| Female | 7 | 10.8 | 64.6 | (25.9-133.1) |  | Female | 26 | 14.7 | 176.5 | (115.3-258.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 6 | 5.2 | 115.0 | (42.0-250.2) |
| Female | 8 | 4.7 | 169.8 | (73.1-334.6) |  | Female | 13 | 4.8 | 270.8 | (144.1-463.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 13 | 15.2 | 85.6 | (45.5-146.4) |
| Female | 115 | 114.6 | 100.4 | (82.9-120.5) |  | Female | 11 | 14.9 | 74.0 | (36.9-132.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 12.1 | 74.1 | (33.8-140.7) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 28.7 | 87.0 | (56.3-128.4) |  |  |  |  |  |  |
| Female | 39 | 32.8 | 118.9 | (84.5-162.5) |  | Female | 17 | 10.3 | 165.7 | (96.4-265.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.8 | 88.3 | (32.3-192.3) |  | Male | 11 | 9.2 | 119.1 | (59.4-213.1) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 10 | 10.9 | 91.9 | (44.0-169.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 117 | 85.8 | 136.4 | (112.8-163.5) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 14.3 | 63.0 | (28.8-119.7) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 14 | 9.2 | 152.0 | (83.0-255.0) |  | Female | 6 | 4.2 | 141.7 | (51.7-308.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 10.8 | 111.1 | (57.3-194.1) |  | Male | 6 | 6.6 | 90.6 | (33.1-197.2) |
| Female | 9 | 8.8 | 102.0 | (46.5-193.6) |  | Female | 33 | 20.8 | 158.4 | (109.0-222.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 9.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 39 | 25.5 | 152.8 | (108.6-208.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 45.7 | 72.2 | (49.7-101.3) |  | Male | 350 | 341.7 | 102.4 | (92.0-113.8) |
| Female | 48 | 56.1 | 85.5 | (63.1-113.4) |  | Female | 435 | 394.5 | 110.3 | (100.1-121.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

198

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

199

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 10.1 | 88.8 | (40.5-168.6) |  | Male | 8 | 6.7 | 118.7 | (51.1-233.9) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 43 | 38.1 | 112.8 | (81.6-152.0) |  | Female | 6 | 4.4 | 137.2 | (50.1-298.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 5.3 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 11.3 | 79.9 | (36.5-151.7) |  |  |  |  |  |  |
| Female | 3 | 8.6 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 33 | 39.3 | 84.0 | (57.8-117.9) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.1 | 114.9 | (46.0-236.7) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 2 | 7.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.9 | 128.5 | (41.4-300.0) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 9.2 | 86.6 | (37.3-170.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 18.8 | 74.3 | (40.6-124.6) |  | Male | 119 | 141.8 | 83.9 | (69.5-100.4) |
| Female | 12 | 16.4 | 73.1 | (37.7-127.7) |  | Female | 103 | 121.4 | 84.8 | (69.2-102.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

200

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.8 | 81.8 | (35.2-161.1) |  | Male | 8 | 6.2 | 128.9 | (55.5-254.0) |
| Female | 6 | 3.7 | 162.0 | (59.1-352.6) |  | Female | 1 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.8 | 278.3 | (89.7-649.6) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.6 | 89.8 | (28.9-209.5) |
| Female | 35 | 40.8 | 85.8 | (59.7-119.3) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.5 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 10.5 | 95.1 | (45.5-174.9) |  |  |  |  |  |  |
| Female | 14 | 11.1 | 126.5 | (69.1-212.3) |  | Female | 6 | 3.7 | 163.4 | (59.7-355.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 0 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 25 | 33.0 | 75.8 | (49.1-111.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.3 | 94.6 | (30.5-220.8) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.9 | 155.8 | (56.9-339.1) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 3 | 7.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 11 | 9.7 | 113.2 | (56.4-202.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 17.2 | 116.1 | (70.9-179.3) |  | Male | 116 | 127.3 | 91.1 | (75.3-109.3) |
| Female | 15 | 19.5 | 77.1 | (43.1-127.2) |  | Female | 120 | 138.2 | 86.8 | (72.0-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

201

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 11 | 18.3 | 60.3 | (30.0-107.8) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 11 | 12.8 | 86.0 | (42.9-153.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

202

# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 4.2 | 165.1 | (66.1-340.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 14 | 15.4 | 91.1 | (49.8-152.8) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 6 | 13.3 | 45.0 | (16.4-97.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

203

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.8 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

204

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 4.5 | 154.8 | (62.0-318.9) |  | Male | 11 | 2.9 | 385.5 | (192.2-689.9) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 16 | 20.3 | 78.9 | (45.1-128.2) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 6.6 | 75.9 | (24.5-177.1) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 20 | 15.8 | 126.8 | (77.4-195.9) |
| Female | 2 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 6 | 4.7 | 128.9 | (47.1-280.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 8.1 | 110.9 | (50.6-210.5) |  | Male | 73 | 59.3 | 123.1 | (96.5-154.8) |
| Female | 6 | 10.7 | 55.9 | (20.4-121.6) |  | Female | 59 | 72.8 | 81.0 | (61.7-104.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

205

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.6 | 75.3 | (32.4-148.4) |  | Male | 20 | 7.2 | 278.8 | (170.2-430.6) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 21 | 5.2 | 407.0 | (251.8-622.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 6 | 2.2 | 268.6 | (98.1-584.7) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 58 | 39.5 | 146.9 | (111.5-189.9) |  | Female | 5 | 4.8 | 103.4 | (33.3-241.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 5.2 | 190.6 | (91.3-350.6) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 11.7 | 68.1 | (29.3-134.2) |  |  |  |  |  |  |
| Female | 11 | 10.1 | 108.7 | (54.2-194.4) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 5 | 3.8 | 132.0 | (42.6-308.1) |
| Female | 4 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 29 | 36.9 | 78.5 | (52.6-112.7) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 4.4 | 182.3 | (78.5-359.3) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 10 | 8.0 | 124.6 | (59.7-229.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 11 | 9.0 | 122.0 | (60.8-218.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 19.2 | 67.6 | (35.9-115.6) |  | Male | 136 | 144.3 | 94.3 | (79.1-111.5) |
| Female | 16 | 18.0 | 89.1 | (50.9-144.7) |  | Female | 162 | 131.8 | 123.0 | (104.8-143.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

206

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 35.1 | 94.0 | (64.7-132.1) |  | Male | 21 | 22.8 | 92.1 | (57.0-140.8) |
| Female | 10 | 13.0 | 76.9 | (36.8-141.4) |  | Female | 21 | 18.9 | 111.0 | (68.7-169.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 7.0 | 143.1 | (68.5-263.2) |  | Male | 5 | 7.1 | 70.4 | (22.7-164.3) |
| Female | 8 | 5.8 | 137.3 | (59.1-270.6) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 14 | 20.4 | 68.6 | (37.5-115.1) |
| Female | 154 | 151.5 | 101.6 | (86.2-119.0) |  | Female | 17 | 18.4 | 92.2 | (53.7-147.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 16.3 | 98.1 | (56.0-159.3) |
| Female | 1 | 5.2 | nc | (nc-nc) |  | Female | 11 | 7.8 | 140.3 | (70.0-251.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 46 | 38.1 | 120.8 | (88.4-161.1) |  |  |  |  |  |  |
| Female | 36 | 39.6 | 91.0 | (63.7-126.0) |  | Female | 21 | 13.2 | 159.1 | (98.4-243.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 9.2 | 130.2 | (67.2-227.4) |  | Male | 10 | 12.3 | 81.1 | (38.8-149.2) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 9 | 12.9 | 69.7 | (31.8-132.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 110 | 114.8 | 95.8 | (78.7-115.5) |
| Female | 2 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 19.3 | 88.2 | (51.3-141.2) |  | Male | 13 | 8.3 | 157.2 | (83.6-268.8) |
| Female | 12 | 11.8 | 101.3 | (52.3-177.0) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 7 | 5.0 | 139.0 | (55.7-286.3) |
| Female | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 14.4 | 76.6 | (38.2-137.1) |  | Male | 16 | 9.0 | 178.2 | (101.8-289.3) |
| Female | 7 | 10.6 | 65.9 | (26.4-135.7) |  | Female | 25 | 28.1 | 89.0 | (57.6-131.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 12.1 | 49.7 | (18.2-108.2) |  |  |  |  |  |  |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 38 | 34.0 | 111.6 | (79.0-153.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 62.2 | 82.0 | (61.0-107.8) |  | Male | 445 | 459.4 | 96.9 | (88.1-106.3) |
| Female | 63 | 70.0 | 89.9 | (69.1-115.1) |  | Female | 493 | 501.7 | 98.3 | (89.8-107.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

207

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 37.6 | 95.8 | (67.1-132.7) |  | Male | 35 | 22.7 | 154.5 | (107.6-214.8) |
| Female | 12 | 13.3 | 89.9 | (46.4-157.1) |  | Female | 15 | 17.2 | 87.2 | (48.8-143.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 6.5 | 138.6 | (63.2-263.1) |  | Male | 8 | 7.2 | 111.8 | (48.2-220.4) |
| Female | 11 | 5.4 | 202.0 | (100.7-361.4) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 22 | 20.4 | 107.7 | (67.5-163.0) |
| Female | 157 | 135.6 | 115.8 | (98.4-135.4) |  | Female | 15 | 17.9 | 83.6 | (46.8-137.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 15.7 | 82.8 | (44.0-141.6) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 7 | 7.5 | 93.3 | (37.4-192.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 39.5 | 73.4 | (49.1-105.4) |  |  |  |  |  |  |
| Female | 35 | 40.6 | 86.2 | (60.1-119.9) |  | Female | 12 | 12.3 | 97.9 | (50.5-171.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 9.3 | 64.3 | (23.5-140.1) |  | Male | 9 | 12.9 | 69.6 | (31.8-132.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 19 | 13.7 | 138.8 | (83.5-216.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 134 | 114.2 | 117.4 | (98.3-139.0) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 18.6 | 75.4 | (41.2-126.5) |  | Male | 5 | 8.6 | 58.2 | (18.8-135.9) |
| Female | 11 | 10.8 | 101.4 | (50.6-181.5) |  | Female | 2 | 5.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 5 | 3.5 | 142.6 | (46.0-332.9) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 14.5 | 75.6 | (37.7-135.3) |  | Male | 9 | 7.9 | 114.2 | (52.1-216.8) |
| Female | 15 | 10.6 | 141.1 | (78.9-232.7) |  | Female | 36 | 22.9 | 157.4 | (110.2-217.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 11.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 28 | 30.6 | 91.7 | (60.9-132.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 63.9 | 64.2 | (46.1-87.1) |  | Male | 425 | 462.0 | 92.0 | (83.4-101.2) |
| Female | 39 | 65.9 | 59.2 | (42.1-80.9) |  | Female | 464 | 470.3 | 98.7 | (89.9-108.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

208

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 3.6 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

209

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 111 | 98.2 | 113.0 | (93.0-136.1) |  | Male | 30 | 62.0 | 48.4 | (32.6-69.1) |
| Female | 37 | 39.4 | 93.9 | (66.1-129.4) |  | Female | 18 | 53.1 | 33.9 | (20.1-53.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 18 | 18.7 | 96.0 | (56.9-151.8) |  | Male | 21 | 19.4 | 108.3 | (67.0-165.5) |
| Female | 14 | 16.8 | 83.2 | (45.4-139.6) |  | Female | 13 | 17.3 | 75.0 | (39.9-128.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 48 | 55.4 | 86.7 | (63.9-115.0) |
| Female | 345 | 397.0 | 86.9 | (78.0-96.6) |  | Female | 43 | 53.3 | 80.7 | (58.4-108.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 54 | 42.8 | 126.1 | (94.7-164.5) |
| Female | 22 | 13.6 | 161.8 | (101.4-245.0) |  | Female | 28 | 22.0 | 127.1 | (84.5-183.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 118 | 103.5 | 114.0 | (94.4-136.5) |  |  |  |  |  |  |
| Female | 111 | 118.9 | 93.4 | (76.8-112.5) |  | Female | 32 | 36.3 | 88.2 | (60.3-124.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 31 | 25.2 | 123.1 | (83.6-174.7) |  | Male | 37 | 33.9 | 109.1 | (76.8-150.3) |
| Female | 11 | 7.5 | 147.2 | (73.4-263.5) |  | Female | 58 | 39.8 | 145.6 | (110.6-188.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 10 | 7.6 | 131.7 | (63.0-242.2) |  | Male | 334 | 314.4 | 106.2 | (95.1-118.3) |
| Female | 3 | 6.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 60 | 51.4 | 116.6 | (89.0-150.1) |  | Male | 40 | 22.7 | 176.5 | (126.1-240.4) |
| Female | 40 | 32.5 | 122.9 | (87.8-167.4) |  | Female | 25 | 15.5 | 161.6 | (104.5-238.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 27 | 14.6 | 185.4 | (122.1-269.7) |  | Male | 9 | 14.1 | 64.0 | (29.2-121.5) |
| Female | 12 | 4.8 | 250.9 | (129.5-438.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 32 | 39.4 | 81.3 | (55.6-114.8) |  | Male | 18 | 23.2 | 77.5 | (45.9-122.5) |
| Female | 21 | 32.2 | 65.1 | (40.3-99.6) |  | Female | 79 | 74.2 | 106.5 | (84.3-132.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 65 | 32.2 | 201.6 | (155.6-256.9) |  |  |  |  |  |  |
| Female | 10 | 11.9 | 83.7 | (40.1-153.9) |  | Female | 89 | 88.8 | 100.3 | (80.5-123.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 251 | 173.8 | 144.4 | (127.1-163.4) |  | Male | 1418 | 1256.5 | 112.9 | (107.1-118.9) |
| Female | 207 | 198.7 | 104.2 | (90.5-119.4) |  | Female | 1349 | 1399.5 | 96.4 | (91.3-101.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

210

# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 14 | 15.7 | 89.4 | (48.9-150.1) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 13 | 14.1 | 92.4 | (49.1-158.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

211

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 10 | 8.7 | 115.6 | (55.3-212.6) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 9.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 5.0 | nc | (nc-nc) |  | Male | 15 | 35.8 | 42.0 | (23.5-69.2) |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 22 | 28.8 | 76.5 | (47.9-115.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

212

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 12 | 15.8 | 76.1 | (39.3-133.0) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 11 | 16.1 | 68.3 | (34.1-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

213